Background: The clinical and pathologic predictors of prostate cancer-specific mortality (PCSM) many years after radical prostatectomy (RP) remain to be fully elucidated. We explored the association between pre-operative prostate-specific antigen (PSA) and other pathologic predictors and PCSM in men who have undergone (RP).
Methods: We report on 459 patients with PCSM data after RP who were followed prospectively over a 23-year period between 1987 and 1997. Cox regression and Kaplan-Meier analysis were used to evaluate pre-operative PSA, pathologic Gleason sum, pathologic stage, and surgical margin status as predictors of PCSM.
Results: The median PSA was 6.6 ng/ml (± 9.9) and the median follow-up time was 9.4 (± 4.9) years. Fourteen patients (3.1%) died of PC. On multivariate analysis, only PSA (HR: 1.050; P = 0.001) and binary Gleason sum (HR: 3.402; P = 0.043) remained significant predictors of PCSM. The predicted 10-year PCSM was significantly worse in those patients in the highest PSA tertile compared to those in other tertiles [PSA > 9.9: 87% (82-92%) vs. PSA = 4-9.9: 95% (93.0-97.0%) vs. PSA = 0-3.9: 100.0% (100.0-100.0%)].
Conclusions: We have highlighted the importance of pre-operative PSA in predicting PCSM many years after RP. It is a more significant predictor than Gleason sum and pathologic stage. Thus, PSA may help identify patients with life-threatening PC at a time when their disease is curable with definitive therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pros.21402 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape.
PLoS One
November 2024
Division of personalised oncology, Walter and Eliza Hall Institute, Melbourne, Australia.
Background: Immunotherapy has demonstrated limited activity in prostate cancer to date. This likely reflects an immune suppressive tumor microenvironment (TME), with previous studies suggesting low PD-L1 expression and a sparse immune cell infiltrate. We aimed to further characterise the immune TME in primary prostate cancer and correlate immune subset densities with clinical outcomes.
View Article and Find Full Text PDFRobot-assisted simple prostatectomy for men with benign prostatic hyperplasia and bothersome LUTS-a retrospective cohort study.
J Robot Surg
November 2024
South Terrace Urology, Adelaide, Australia.
BPH is a common urological pathology that affects 2480 per 100,000 men worldwide. With a rising population and increased age expectancy, the prevalence of benign prostatic hyperplasia (BPH) is increasing (Awedew et al. in Lancet Healthy Longev 3(11), 2022).
View Article and Find Full Text PDFLow SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.
Prostate
February 2025
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- SWI/SNF complexes are multi-subunit chromatin remodelers linked to disruptions in over 20% of human tumors, with specific attention given to the SMARCD family in prostate cancer.
- A study using immunohistochemistry on tissue samples found that SMARCD1 and SMARCD3 protein levels were significantly higher in tumor tissues compared to benign tissues, particularly in lymph node metastases.
- While SMARCD1 did not correlate with clinical outcomes, low SMARCD3 levels were associated with increased progression to metastasis, suggesting potential roles as biomarkers in prostate tumorigenesis.
Impact of Cryopreserved Placental Allografts on Biochemical Recurrence in Prostate Cancer.
Cancers (Basel)
August 2024
Department of Urologic Oncology, Providence Saint John's Cancer Institute, Santa Monica, CA 90404, USA.
Background: Human placental allografts are widely used to promote wound healing. Placental (or amniotic membrane/umbilical cord) allografts are placed along the neurovascular bundles during radical prostatectomy to improve continence and erectile function recovery. It is unknown whether placental allografts impact biochemical recurrence (BCR).
View Article and Find Full Text PDFPrevalence and potential predictors of incidental prostate Cancer in patients undergoing surgery for Benign Prostatic obstruction: a retrospective study in the MRI era.
World J Urol
August 2024
Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico di Roma, via Alvaro del Portillo, 200, Rome, 00128, Italy.
Article Synopsis
- A study was conducted to examine the prevalence of incidental prostate cancer (IPCa) in patients who underwent surgery for benign prostatic obstruction (BPO), revealing that 16.3% of those had IPCa, even with negative exams.
- The research utilized data from patients treated at a major center between January 2020 and December 2022, including factors like PSA levels and previous imaging results to identify potential predictors of IPCa occurrence.
- Findings suggest that higher PSA density (PSAd) is linked to more severe cancer, while negative mpMRI scans appear to lower the chances of clinically significant prostate cancer; these results prompt a reconsideration of current urology guidelines if confirmed by further studies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!